A Mechanical Immune Checkpoint Inhibitor Stiffens Tumor Cells to Potentiate Antitumor Immunity

Area of Science:

• Biophysics
• Immunology
• Cancer Biology

Background:

• Tumor progression is linked to decreased tumor cell stiffness, making them less susceptible to immune attack.
• Elevated cholesterol in tumor cell membranes contributes to their softness.
• Targeting tumor cell mechanics offers a novel therapeutic strategy.

Purpose of the Study:

• To develop and evaluate a mechanical immune checkpoint inhibitor (MICI) for enhancing anti-tumor immunity.
• To investigate the impact of modulating tumor cell stiffness on lymphocyte activation.
• To explore the combination of MICIs with existing immunotherapies.

Main Methods:

• Formulation of MICI using cyclodextrin (CD) lipids and fusogenic lipids.
• Liposome-mediated delivery of CD lipids to fuse with tumor cell membranes.
• Assessment of tumor cell stiffness, lymphocyte activation (NK and T cells), and anti-tumor efficacy in mouse models.
• Analysis of cholesterol content in tumor cell membranes.

Main Results:

• MICI treatment reduced tumor cell membrane cholesterol, leading to increased cell stiffness.
• Stiffened tumor cells exhibited enhanced lymphocyte activation, including degranulation and cytokine production.
• MICI treatment improved anti-tumor efficacy in breast cancer and melanoma mouse models, especially when combined with immunotherapies.
• The mechanism involves direct regulation of tumor cell stiffness impacting lymphocyte activation.

Conclusions:

• Modulating tumor cell mechanics via MICIs represents a viable strategy to overcome immune evasion.
• Targeting the mechanical properties of tumor cells can potentiate lymphocyte-mediated anti-tumor responses.
• This research highlights a new mechanical dimension in regulating immune cell activation and anti-tumor immunity.